These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1114 related articles for article (PubMed ID: 19255025)

  • 1. Evaluation of vaccine coverage for low birth weight infants during the first year of life in a large managed care population.
    Batra JS; Eriksen EM; Zangwill KM; Lee M; Marcy SM; Ward JI;
    Pediatrics; 2009 Mar; 123(3):951-8. PubMed ID: 19255025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipolyribosyl ribitol phosphate response of premature infants to primary and booster vaccination with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus/Haemophilus influenzae type b vaccine.
    Omeñaca F; Garcia-Sicilia J; García-Corbeira P; Boceta R; Torres V
    Pediatrics; 2007 Jan; 119(1):e179-85. PubMed ID: 17145903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue.
    Omeñaca F; Garcia-Sicilia J; García-Corbeira P; Boceta R; Romero A; Lopez G; Dal-Ré R
    Pediatrics; 2005 Dec; 116(6):1292-8. PubMed ID: 16322149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of DTaP-IPV-HIb-HBV hexavalent vaccine in very premature infants.
    Faldella G; Galletti S; Corvaglia L; Ancora G; Alessandroni R
    Vaccine; 2007 Jan; 25(6):1036-42. PubMed ID: 17088013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a combination diphtheria, tetanus toxoid, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine coadministered with a 7-valent pneumococcal conjugate vaccine and a Haemophilus influenzae type b conjugate vaccine.
    Pichichero ME; Bernstein H; Blatter MM; Schuerman L; Cheuvart B; Holmes SJ;
    J Pediatr; 2007 Jul; 151(1):43-9, 49.e1-2. PubMed ID: 17586189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Seroconversion after vaccination against pertussis, Haemophilus influenzae type b and poliomyelitis in preterm infants].
    Sikora JP; Chlebna-Sokół D
    Przegl Lek; 2003; 60(11):699-703. PubMed ID: 15058036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age.
    Nolan T; Bernstein H; Blatter MM; Bromberg K; Guerra F; Kennedy W; Pichichero M; Senders SD; Trofa A; Collard A; Sullivan DC; Descamps D
    Pediatrics; 2006 Sep; 118(3):e602-9. PubMed ID: 16950952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diphtheria, pertussis, poliomyelitis, tetanus, and Haemophilus influenzae type b vaccinations and risk of eczema and recurrent wheeze in the first year of life: the KOALA Birth Cohort Study.
    Kummeling I; Thijs C; Stelma F; Huber M; van den Brandt PA; Dagnelie PC
    Pediatrics; 2007 Feb; 119(2):e367-73. PubMed ID: 17272598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of a decline in Colorado Medicaid managed care enrollment on access and quality of preventive primary care services.
    Berman S; Armon C; Todd J
    Pediatrics; 2005 Dec; 116(6):1474-9. PubMed ID: 16322173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and reactogenicity of DTPa-HBV-IPV/Hib vaccine as primary and booster vaccination in low-birth-weight premature infants.
    Vázquez L; Garcia F; Rüttimann R; Coconier G; Jacquet JM; Schuerman L
    Acta Paediatr; 2008 Sep; 97(9):1243-9. PubMed ID: 18489623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
    Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
    Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody response of low birth weight infants to Haemophilus influenzae type b polyribosylribitol phosphate-outer membrane protein conjugate vaccine.
    Munoz A; Salvador A; Brodsky NL; Arbeter AM; Porat R
    Pediatrics; 1995 Aug; 96(2 Pt 1):216-9. PubMed ID: 7630672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of an increase in cardiorespiratory events after diphtheria-tetanus-acellular pertussis immunization in preterm infants: a randomized, multicenter study.
    Carbone T; McEntire B; Kissin D; Kelly D; Steinschneider A; Violaris K; Karamchandani N
    Pediatrics; 2008 May; 121(5):e1085-90. PubMed ID: 18450851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination vaccine use and vaccination quality in a managed care population.
    Happe LE; Lunacsek OE; Marshall GS; Lewis T; Spencer S
    Am J Manag Care; 2007 Sep; 13(9):506-12. PubMed ID: 17803364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of combined diphtheria tetanus whole cell pertussis hepatitis B/ Haemophilus influenzae type b vaccine in Indian infants.
    Bavdekar SB; Maiya PP; Subba Rao SD; Datta SK; Bock HL
    Indian Pediatr; 2007 Jul; 44(7):505-10. PubMed ID: 17684303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit.
    Dylag AM; Shah SI
    Pediatrics; 2008 Sep; 122(3):e550-5. PubMed ID: 18762489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.
    Ciarlet M; He S; Lai S; Petrecz M; Yuan G; Liu GF; Mikviman E; Heaton PM; Panzer F; Rose T; Koller DY; Van Damme P; Schödel F
    Pediatr Infect Dis J; 2009 Mar; 28(3):177-81. PubMed ID: 19209092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.